Khalid Ali Shah

USPTO Granted Patents = 27 (Patent Applications = 19)

CIPO Patents = 1

EPO Patents = 5 (Patent Applications = 8)

Average Co-Inventor Count = 2.3

ph-index = 7

Forward Citations = 217(Granted Patents)

Location History:

Calgary, CA (2013)
Houston, TX (US) (2016)
South San Francisco, CA (US) (2017 - 2020)
Half Moon Bay, CA (US) (2017 - 2024)

Company Filing History:

Clearwater International LLC

patents

4. 3 out of 832,680

Other

patents

Years Active: 2013-2025

Loading Chart...

27 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12486233 - Crystalline Solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use (2025-12-02),

2. 12227481 - Crystalline solid forms of salts of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use (2025-02-18),

3. 12128039 - Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds (2024-10-29),

4. 12017995 - Crystalline forms and salt forms of a kinase inhibitor (2024-06-25),

5. 12016854 - Liquid dosage forms to treat cancer (2024-06-25),

6. 11760726 - Crystalline solid forms of N-{4-[(6,7-Dimethoxyquinolin-4-yl)oxy]phenyl} -n'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use (2023-09-19),

7. 11731941 - Crystalline solid forms of salts of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use (2023-08-22),

8. 11724986 - Crystalline solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use (2023-08-15),

9. 11504362 - Liquid dosage forms to treat cancer (2022-11-22),

10. 11298349 - Processes for preparing quinoline compounds and pharmaceutical compositions containing such compounds (2022-04-12),

11. 11279675 - Crystalline solid forms of salts of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl) cyclopropane-1, 1-dicarboxamide, processes for making, and methods of use (2022-03-22),

12. 11123338 - C-met modulator pharmaceutical compositions (2021-09-21),

13. 10851061 - Crystalline solid forms of N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide, processes for making, and methods of use (2020-12-01),

14. 10813936 - Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-YL)-pyrazolo[1,5-A]pyrimidin-3-YL)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate (2020-10-27),

15. 10799505 - Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate (2020-10-13),

Sure, I can help you with that. Here is the article about inventor Khalid Ali Shah:

Title: Innovator Spotlight: Khalid Ali Shah from Houston, TX

Introduction:

Khalid Ali Shah, a prolific inventor based in Houston, Texas, is renowned for his groundbreaking work in the field of pharmaceuticals. With an impressive portfolio of 24 patents, Khalid has made significant contributions to the field of drug development and treatment.

Latest Patents:

Among his latest patents is the development of crystalline forms and salt forms of a kinase inhibitor. This invention revolves around solid polymorphs of the free base and salts of Compound 1, a c-Met inhibitor. Additionally, Khalid has also patented a liquid pharmaceutical composition comprising cabozantinib to treat advanced urothelial cancer or renal cell carcinoma.

Career Highlights:

Having worked with esteemed companies such as Exelixis, Inc. and Array Biopharma Inc., Khalid Ali Shah has garnered invaluable experience in the pharmaceutical industry. His innovative research and development have led to the creation of novel drug formulations with the potential to revolutionize cancer treatment.

Collaborations:

During his career, Khalid has collaborated closely with industry experts and researchers. Notable coworkers include Jo Ann Wilson and Alisha B. Arrigo, with whom Khalid has shared his knowledge and expertise to drive advancements in drug discovery and development.

Conclusion:

In conclusion, Khalid Ali Shah stands as a trailblazer in the field of pharmaceutical innovation, with a rich history of patents and contributions to the advancement of cancer treatment. His relentless pursuit of scientific excellence has positioned him as a key figure in the industry, shaping the future of healthcare through groundbreaking inventions.

This text is generated by artificial intelligence and may not be accurate.